REGULAR CONTENT
Final ID
430
Type
Original Scientific Research-Oral or Pos
Authors
M Tal1, G Bartal2
Institutions
1Assuta Hospital, Tel Aviv, Israel, 2Meir Medical Center, Kfar Saba, Israel
Purpose
Dialysis access management is often time and radiation intensive requiring repeated contrast material injections and catheter exchanges. We report initial clinical experience with a novel, FDA approved high pressure angioplasty balloon catheter (Chameleon™) that has an integrated proximal injection technology, which allows contrast injection via either inflated or deflated balloon catheter.
Materials & Methods
The Chameleon™angioplasty balloon catheter was used in a total 106 patients at 6 sites, by 12 endovascular interventionists. Data was collected prospectively and included patient demographics, type of intervention, access site, antegrade or retrograde access and use of a vascular sheath. Grading by the operating interventionists was performed for radiation exposure, procedure time and number of catheter and wire exchange.
Results
There were no device malfunctions or balloon ruptures. 93/106 (88%) of procedures were fistula and grafts angioplasty, 9/106 (9%) were declotting and 13/106 (12%) were fibrin sheath disruption. 48/106 (45%) of the procedures were performed sheathless, without the use of a vascular sheath. In declotting procedures no mechanical maceration or thrombectomy devices were used. Procedure time and number of catheter exchanges were reduced in (46%) and (72%) of cases respectively. Substantial reduction of fluoroscopy time was reported in 50% of cases, primarily the more complicated ones.
Conclusions
Proximal injection technology balloon catheter is safe in a variety of dialysis access management cases and shows potential reduction of procedure time and radiation exposure. Further, large scale evaluation is ongoing.
Final ID
430
Type
Original Scientific Research-Oral or Pos
Authors
M Tal1, G Bartal2
Institutions
1Assuta Hospital, Tel Aviv, Israel, 2Meir Medical Center, Kfar Saba, Israel
Purpose
Dialysis access management is often time and radiation intensive requiring repeated contrast material injections and catheter exchanges. We report initial clinical experience with a novel, FDA approved high pressure angioplasty balloon catheter (Chameleon™) that has an integrated proximal injection technology, which allows contrast injection via either inflated or deflated balloon catheter.
Materials & Methods
The Chameleon™angioplasty balloon catheter was used in a total 106 patients at 6 sites, by 12 endovascular interventionists. Data was collected prospectively and included patient demographics, type of intervention, access site, antegrade or retrograde access and use of a vascular sheath. Grading by the operating interventionists was performed for radiation exposure, procedure time and number of catheter and wire exchange.
Results
There were no device malfunctions or balloon ruptures. 93/106 (88%) of procedures were fistula and grafts angioplasty, 9/106 (9%) were declotting and 13/106 (12%) were fibrin sheath disruption. 48/106 (45%) of the procedures were performed sheathless, without the use of a vascular sheath. In declotting procedures no mechanical maceration or thrombectomy devices were used. Procedure time and number of catheter exchanges were reduced in (46%) and (72%) of cases respectively. Substantial reduction of fluoroscopy time was reported in 50% of cases, primarily the more complicated ones.
Conclusions
Proximal injection technology balloon catheter is safe in a variety of dialysis access management cases and shows potential reduction of procedure time and radiation exposure. Further, large scale evaluation is ongoing.